☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
OncXerna Therapeutics
OncXerna Therapeutics Reports P-II Trial Results of Bavituximab + Pembrolizumab and New Xerna TME Panel Biomarker Data for Advance...
January 24, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.